1. Home
  2. VAL vs GPCR Comparison

VAL vs GPCR Comparison

Compare VAL & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valaris Limited

VAL

Valaris Limited

HOLD

Current Price

$97.48

Market Cap

6.3B

Sector

Energy

ML Signal

HOLD

Logo Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc.

HOLD

Current Price

$55.26

Market Cap

6.3B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VAL
GPCR
Founded
1975
2016
Country
Bermuda
United States
Employees
5642
N/A
Industry
Oil & Gas Production
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
6.3B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
VAL
GPCR
Price
$97.48
$55.26
Analyst Decision
Hold
Strong Buy
Analyst Count
5
11
Target Price
$63.50
$103.36
AVG Volume (30 Days)
1.2M
789.5K
Earning Date
01-01-0001
05-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$15.62
N/A
P/E Ratio
$16.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.15
$13.24
52 Week High
$102.20
$94.90

Technical Indicators

Market Signals
Indicator
VAL
GPCR
Relative Strength Index (RSI) 63.98 33.81
Support Level $45.71 $18.36
Resistance Level $102.20 $93.91
Average True Range (ATR) 4.00 3.48
MACD -1.02 -0.29
Stochastic Oscillator 88.96 26.86

Price Performance

Historical Comparison
VAL
GPCR

About VAL Valaris Limited

Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Share on Social Networks: